Detail akcie Zealand Pharma online

Business Summary: Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Zealand Pharma A/S revenues increased from DKR53.6M to DKR9.15B. Net income totaled DKR6.83B vs. loss of DKR787.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest Income increase of 93% to DKR206.9M (income), FV Adjustments of Financial Investments increase of 14% to DKR36.4M (income).